These findings reinforce many things that we already know: that mutations acquire gradually with age, that most of the mutations in AML (and
likely other tumors) are random background events not contributing to
tumorigenesis, and that subsequent mutation and evolution can give rise to subclones that ultimately determine cancer progression and response to therapy.